Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Trinity Biotech (TRIB) Gross Margin (2016 - 2024)

Trinity Biotech's Gross Margin history spans 16 years, with the latest figure at 30.76% for Q4 2024.

  • On a quarterly basis, Gross Margin fell 325.0% to 30.76% in Q4 2024 year-over-year; TTM through Dec 2024 was 34.83%, a 61.0% increase, with the full-year FY2025 number at 38.57%, up 374.0% from a year prior.
  • Gross Margin hit 30.76% in Q4 2024 for Trinity Biotech, down from 35.03% in the prior quarter.
  • Over the last five years, Gross Margin for TRIB hit a ceiling of 52.4% in Q3 2020 and a floor of 2.1% in Q3 2022.
  • Historically, Gross Margin has averaged 36.84% across 5 years, with a median of 37.31% in 2021.
  • Biggest five-year swings in Gross Margin: tumbled -3835bps in 2022 and later soared 2707bps in 2023.
  • Tracing TRIB's Gross Margin over 5 years: stood at 47.79% in 2020, then dropped by -22bps to 37.08% in 2021, then decreased by -8bps to 34.18% in 2022, then decreased by 0bps to 34.01% in 2023, then fell by -10bps to 30.76% in 2024.
  • Business Quant data shows Gross Margin for TRIB at 30.76% in Q4 2024, 35.03% in Q3 2024, and 36.19% in Q2 2024.